SLC16A7 and Familial prostate cancer: In prostate cancer research, AR-C155858, an inhibitor of MCT1 and MCT2, has been shown to result in a significant decrease in proliferation and increased apoptosis in murine tumor tissues with no significant effect on benign tissue [115].